D. Boral Capital Reaffirms “Buy” Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $18.00 target price on the stock.

A number of other research analysts have also issued reports on GOVX. Alliance Global Partners assumed coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Trading Down 0.9 %

Shares of NASDAQ:GOVX opened at $2.22 on Thursday. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18. The firm has a fifty day moving average price of $2.48 and a 200 day moving average price of $2.80.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million for the quarter, compared to analyst estimates of $1.84 million. During the same quarter last year, the company posted ($4.80) EPS. On average, research analysts forecast that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC acquired a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent SEC filing. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.